Cases show improved treatment plan and reduction of severe motor disturbances in two patients after undergoing genetic testing
KING OF PRUSSIA, PA – January 15, 2015 - Genomind, a personalized medicine company, is proud to announce that a company co-authored two case series, titled “The Role of Pharmacogenetic Testing in the Amelioration of Antidepressant-Related Motor Disturbances in 2 Young Adult Men With Major Depressive Disorder,” has been accepted for publication in the Primary Care Companion for CNS Disorders.
The two case series, authored by Karen H. Rhea, MD, Chief Medical Officer, Centerstone; William M. Petrie, MD, Director of Geriatric Psychiatry, Vanderbilt University School of Medicine; and Kathryn R. Gardner, MS, Scientific & Clinical Research Analyst, Genomind, demonstrates the utility of genetic testing in clinical practice to help identify effective treatment plans in psychiatric patients. The Genecept™ Assay, a saliva-based genetic test, offered by Genomind, Inc., was utilized in this case series.
The case series abstract can be viewed online here. This report is unique in that it describes 2 young adult men who suffered from depressive symptoms and also experienced severe motor disturbances, which had a profound impact on their daily lives. Genetic testing was able to shed light on why these young men may have experienced previous medication failures, as well as severe motor side effects. After testing, both men were placed on medication regimes which led to complete remission of both depression symptoms and motor side effects. These men were able to reinitiate productive and active lives in college and thereafter.
“Centerstone is very excited to offer pharmacogenomics testing,“ said Dr. Rhea. “Our primary goal is to provide treatments that work to our psychiatric patients, and this provides improved decision-making capability about selection of medication. Time is of the essence in reclaiming lives.”
The Primary Care Companion for CNS Disorders is an online, peer-reviewed, abstracted publication designed to inform and educate primary care physicians and other health care professionals who treat patients suffering from mental and neurological illnesses.
About the Genecept Assay
The Genecept Assay is a comprehensive, simple-to-use tool for understanding genetic and biological markers that best inform response to different psychiatric treatments. The Assay is Genomind’s core product, and contains a proprietary panel of biomarker tests, an analytic report, and a psychopharmacologist consultation. The Assay can be used for a range of psychiatric conditions including depression, bipolar disorder, schizophrenia, anxiety disorders, OCD and ADHD. For more information on the Assay, including information about the specific genes in the panel, please visit http://www.genomind.com/intro-to-personalized-medicine/.
Genomind is a personalized medicine company, comprised of innovative researchers and expert leaders in psychiatry and neurology. Genomind is committed to discovery of the underlying causes of neuropsychiatric disorders and supports the development of personalized medicine that improves patients’ lives. Genomind was founded by Ronald I. Dozoretz, MD, a psychiatrist who has devoted his career to improving mental health. Jay Lombard, DO, a neurologist and co-founder of Genomind, is a critically acclaimed author and nationally recognized thought leader in neuropsychiatry practice and research. Learn more at http://www.genomind.com.
Centerstone, a not-for-profit organization, provides a range of mental health and addiction services to people of all ages for over 55 years. Through more than 50 facilities and 160 partnership locations across Middle Tennessee, Centerstone serves 50,000 children, adolescents, adults, and seniors each year. Centerstone is accredited by CARF International and is a member organization of the National Football League’s NFL Life Line. Learn more at http://www.centerstone.org.
For more information, contact:
Marketing Manager, Genomind